Short Interest in Vor Biopharma Inc. (NYSE:VOR) Increases By 51.8%

Vor Biopharma Inc. (NYSE:VOR) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 4,190,000 shares, a growth of 51.8% from the May 15th total of 2,760,000 shares. Based on an average trading volume of 1,980,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 5.5% of the company’s shares are short sold.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after buying an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP acquired a new stake in Vor Biopharma during the 4th quarter worth approximately $707,000. Jane Street Group LLC acquired a new stake in Vor Biopharma during the 1st quarter worth approximately $140,000. Two Sigma Investments LP lifted its holdings in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after purchasing an additional 25,930 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares during the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Stock Performance

Shares of NYSE VOR opened at $0.21 on Wednesday. Vor Biopharma has a 52 week low of $0.13 and a 52 week high of $1.80. The stock has a market capitalization of $25.77 million, a PE ratio of -0.12 and a beta of -0.51. The stock has a 50 day moving average price of $0.39 and a 200 day moving average price of $0.85.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Citizens Jmp downgraded Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Friday, May 9th. Jones Trading downgraded Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. HC Wainwright reiterated a “neutral” rating on shares of Vor Biopharma in a report on Friday, May 9th. Oppenheimer reiterated an “outperform” rating and set a $8.00 price objective on shares of Vor Biopharma in a report on Friday, March 21st. Finally, Wedbush reiterated a “neutral” rating and set a $0.40 price objective (down from $7.00) on shares of Vor Biopharma in a report on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $7.06.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.